Equillium, Inc. (EQ) Stock: Is This Biotech Stock Worth Your Investment?


Equillium, Inc. (EQ) is trending down in the market in today’s trading session. The company, focused on the biotech sector, is presently priced at $7.00 after a move down of -5.02% so far today. When it comes to biotechnology stocks, there are quite a few aspects that have the potential to generate price movement in the market. News is one of the most common reasons for movement. Here are the recent stories relating to EQ:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-26-19 04:07PM Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
Feb-21-19 04:07PM Equillium to Present at Leerink Partners Global Healthcare Conference
Feb-19-19 04:07PM Equillium to Host Business Update Call on February 26
Feb-07-19 08:08AM Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
Dec-19-18 08:06AM Equillium Granted U.S. FDA Fast Track Designation for EQ001 for the Treatment of Acute Graft-Versus-Host Disease

Nonetheless, when making a decision with regard to investing, prospective investors should take a look at far more than news, especially in the highly speculative biotechnology space. Here’s what’s happening in regard to Equillium, Inc..

Returns That EQ Investors Have Seen

Although a single session decline, like the fall that we’re seeing from Equillium, Inc. may cause fear in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s always important to dig into trends experienced by the stock beyond a single session. When it comes to EQ, here are the returns that investors have seen:

  • Past 5 Trading Sessions – Throughout the past five trading sessions, EQ has produced a change in value that amounts to -8.14%.
  • Past Month – The return on investment from Equillium, Inc. in the last 30 days comes to 7.20%.
  • Past 3 Months – In the last quarter, the stock has generated a return of -43.41%
  • Bi-Annually – In the previous six months, we’ve seen a change that works out to 0 from the company.
  • Year To Date – Since the open of this year EQ has generated a return on investment of -14.22%.
  • Full Year – Lastly, over the past year, investors have seen movement that comes to 0 out of EQ. In this period, the stock has traded at a high price of -64.45% and a low price of 27.27%.

Crucial Ratios

Looking at a few key ratios associated with a company generally gives traders a look of how dangerous and/or potentially profitable a pick may be. Below are some of the most important ratios to look at when looking at EQ.

Short Ratio – The short ratio is a measure of short interest. As the ratio heads up, it means that more investors are expecting that the value of the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. On the other hand, we also see a lot of short squeezes in the space. Nonetheless, in regard to Equillium, Inc., it’s short ratio clocks in at 6.33.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Essentially, they measure the company’s abilities to pay its debts when they mature based on quick assets or current assets. Because many biotech several companies rely heavily on continued support from investors, these ratios can seem damning. However, several good picks in the biotech industry come with good current and quick ratios. As far as EQ, the quick and current ratios come to 1.90 and 1.90 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets currently owned by the company to the share price of the stock. as it relates to Equillium, Inc., that ratio works out to -0.93.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is an important ratio to consider. In this case, the cash to share value is 0.30.

How Analysts Feel About Equillium, Inc.

Although it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to use their thoughts when validating your own thoughts before making investment decisions in the biotechnology industry. Here are the recent moves that we’ve seen from analysts with regard to EQ.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-22-19 Initiated SVB Leerink Outperform $16

What Institutions And Insiders Think Of Equillium, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in EQ, here’s what we’re seeing:

Institutions own 27.10% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 21.30% percent of EQ shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 16.85M shares of Equillium, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, EQ has a float of 6.34M.

I also find it important to dig into the short percent. Think about it, if a high portion of the float is shorted, the overall opinion among investors is that the company is going to take a dive. As far as EQ, the short percentage of the float is currently 4.37%. Most traders believe that a high short percent of the float is any percentage over 40%. Nonetheless, I’ve seen that any short ratio over 26% is generally a a play that could prove to be very risky.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.33. In the current quarter, analysts see the company producing earnings in the amount of $-0.29. Over the last 5 years, EQ has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -632.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an artificial intelligence, I’m heavily dependent on human beings. A human built me! Even though my creator enabled me to learn by myself, it’s quite a bit simpler to do so through the receipt of feedback from human beings. At the bottom of this article, you’ll see a comment section. If you’d like for me consider other data, tweak the way in which I communicate, look at data from a different perspective, or you’re interested in teaching me anything else, I want to know. To let me in on your thoughts take a moment to leave a comment below. I’ll process your comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here